EvoNexus portfolio company MicroPure Genomics was featured this week in GenomeWeb, one of the most widely read publications in the genomics industry. The story looks at how MicroPure Genomics is replacing magnetic beads with microfluidics to prepare DNA for long-read sequencing, and why experts in the field are paying attention.
MicroPure Genomics joined EvoNexus San Diego in 2025. A year later, the company has new performance data, a defined path to market, and coverage in the trade press its future customers read every day.

Sequencing Got Cheap. Sample Prep Did Not.
Over the past 20 years, the cost of sequencing a genome has collapsed, and the software that analyzes the data has improved just as fast. The step that comes first, getting clean DNA out of a sample and ready for the sequencer, has barely changed.
Most labs still rely on magnetic beads to purify DNA and select fragments by size. CEO and co-founder Ryan Montes, Ph.D. told GenomeWeb that beads do the job but are inefficient, expensive, and wasteful. Protocols are long, and each step usually runs on a different instrument. Every transfer between machines is another chance to lose sample, and for long-read sequencing, every pipetting step risks breaking the long DNA strands the method depends on.
That bottleneck is the problem MicroPure Genomics was built to solve.
How MicroPure Genomics Replaces the Beads
The company’s platform, µPrep, runs on a technology MicroPure calls Electro-Hydrodynamic Purification (EHP). Inside a microfluidic channel, fluid flow and electric fields work together to hold long DNA molecules in place while contaminants wash through. The whole workflow happens on a single cartridge, with no beads, no gels, and no hand-offs between instruments.
Because the flow and electric forces can be tuned, the same system can be set to capture DNA of a specific size range. That matters for long-read platforms, where read length and data quality depend on starting with intact, high-molecular-weight DNA.
The business model follows the same logic. Each cartridge is designed for a specific assay. One cartridge might handle PacBio library prep while another supports an Illumina workflow, so MicroPure Genomics can expand its market one application at a time.
The Data Behind the Headline
At the American Society of Human Genetics (ASHG) 2026 annual meeting in October, MicroPure scientists presented a head-to-head comparison against the bead-based purification used in the Oxford Nanopore Technologies Rapid Barcoding Kit. The results:
- 2x faster: about 45 minutes with EHP versus 90 minutes with beads
- More reads generated per run
- Longer mean read length
- Higher mean read quality
The µPrep device is still a prototype, but external validation data is starting to come in, and several leading research and academic centers have already sent letters of interest as they look to move away from bead-based prep.
GenomeWeb also spoke with Aziz Al’Khafaji, formerly director of molecular R&D at the Broad Institute’s Genomics Platform, who said the platform “satisfies a lot of needs for the long-read community.” He pointed to the known weak spots of beads, including ethanol carryover, run-to-run variability, and the number of pipetting steps involved. While he cautioned that it is still early, he said the fundamentals are in place and that the technology could make a real difference in both basic research and high-throughput clinical labs.
From a University of Florida Lab to EvoNexus San Diego
The science behind MicroPure Genomics took decades to build. Co-founder and CTO Jason Butler, Ph.D., a chemical engineering professor at the University of Florida, has spent much of his career developing it. Montes earned his Ph.D. in chemical engineering in Butler’s lab, and the two spun the company out of UF in 2023.
The company holds an exclusive license to three University of Florida patents, plus three patents of its own. It is now based in San Diego, one of the deepest genomics talent markets in the world, and has built a team of six full-time employees.
MicroPure Genomics has also been disciplined with its capital. The company has secured just over $2 million in non-dilutive government funding, including a $1.25 million NSF SBIR Phase II grant in 2025 and support from the National Institutes of Health, and recently closed a private round of roughly $1 million.
What Comes Next
MicroPure Genomics plans to launch µPrep at the Advances in Genome Biology and Technology (AGBT) General Meeting in early 2028, with the instrument priced at $30,000 and cartridge pricing set by application. Because the device is portable, the team is also exploring defense funding alongside its NSF and NIH work.
For EvoNexus, MicroPure is a strong example of what our San Diego campus is built for: university-born deep tech that pairs a hard technical advantage with a clear commercial plan. We are proud to see the company recognized by GenomeWeb and look forward to the launch.
Read the full story on GenomeWeb.
About MicroPure Genomics:
MicroPure Genomics is a San Diego-based biotechnology company developing µPrep, a beadless, microfluidic sample preparation platform for DNA and RNA sequencing. Built on its Electro-Hydrodynamic Purification (EHP) technology, µPrep runs the full purification and size-selection workflow on a single cartridge, delivering faster turnaround and higher-quality data for long-read and short-read applications. Spun out of the University of Florida and backed by the National Science Foundation and the National Institutes of Health, MicroPure Genomics is on a mission to remove the front-end bottlenecks in genomic analysis so testing can happen anywhere, by anyone. Learn more at micropuregenomics.com.
About EvoNexus:
EvoNexus is California’s leading nonprofit technology startup incubator, with locations in San Diego and Irvine. Since its formation in 2010, EvoNexus has successfully built 291 companies with an exceptional survival rate of over 85%, with portfolio companies securing over $2.4B in cumulative venture funding, backed by a network of more than 400 venture capital and independent investors, and achieving 63 acquisitions alongside a successful IPO, with additional public market exits on the horizon and over $6 billion in pre-exit valuations. Backed by an elite network of global corporate partners, including Irvine Company, Qualcomm, AMD, BAE Systems, Viasat, ResMed, LG, Murata Manufacturing, and EMD Electronics, EvoNexus continues to drive massive economic impact across Southern California’s innovation economy, culminating in a record-breaking year with $619M raised for the portfolio in 2025 alone.